Status:
UNKNOWN
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Melanoma
Non-small Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Prospective, monocentric clinical study. Patients selected for nivolumab therapy in AP-HM for melanoma and non-small cell lung cancer will be eligible. Do not include patients with conditions that do ...
Eligibility Criteria
Inclusion
- patients treated with nivolumab
Exclusion
- Age \<18 years
- Preliminary cardiac disease with FeVG \<50%
- Cardiomyopathy dilated, hypertrophic or restrictive
- History of cardiac arrhythmia
- History of cardiac toxicity under another anti-cancer treatment
- Known coronary disease
- History of stroke less than 3 months old
- Patient not wishing to participate in the study
- Vulnerable persons (pregnant women, adults under guardianship or guardianship, persons deprived of their liberty)
Key Trial Info
Start Date :
April 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03313544
Start Date
April 9 2018
End Date
March 1 2025
Last Update
April 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hopitaux de Marseille
Marseille, France, 13354